Clinical study on levofloxacin combined with anti tuberculosis chemotherapy in the treatment of retreated smear positive pulmonary tuberculosis
10.3969/j.issn.1006-5725.2015.18.014
- VernacularTitle:左氧氟沙星联合抗结核化疗方案治疗复治涂阳肺结核的临床研究
- Author:
Bing LIANG
;
Hong WU
;
Jingyi SU
;
Caiyun DU
;
Ruixia HUANG
- Publication Type:Journal Article
- Keywords:
Pulmonary tuberculosis;
Recurrent smear positive;
Anti tuberculosis chemotherapy;
Levofloxacin
- From:
The Journal of Practical Medicine
2015;(18):2981-2984
- CountryChina
- Language:Chinese
-
Abstract:
Objective Investigate the clinical efficacy of treating retreated smear-positive tuberculosis patients with conventional anti-tuberculosis chemotherapy combined with levofloxacin. Methods Divide 60 retreated smear-positive tuberculosis patients registered in our hospital between October 2012 and October 2014 into two groups using random number table method: levofloxacin group and conventional treatment group. Each group contains 30 patients that were treated for 9 months , and the efficacy the both treatment methods were compared. Results The sputum conversion rate in the levofloxacin group is 93.33% and 96.67% after treating for 6 months and 9 months , respectively; which are substantial higher than that of the conventional treatment group with sputum conversion rate of 70% and 73.33% after 6 months and 9 months of treatment , respectively (P < 0.05). The absorption rate of the levofloxacin group is significantly higher than that of the conventional treatment group (P < 0.05). The cavity improvement rate of the levofloxacin group is 73.33%, which is significantly higher than that of the conventional treatment group (33.33%) (P < 0.05). The clinical efficacy of the LVFX group is substantially higher than the routine treatment group (P < 0.05). The overall effectiveness of LVFX group reached 100% , which is significantly higher than that of the conventional treatment group (86.67%) (P < 0.05). Conclusions Levofloxacin combined with conventional anti-tuberculosis chemotherapy can effectively improve the clinical efficacy in the treatment of tuberculosis.
